A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL)

This phase 2 experimental protocol is a non-profit study designed to evaluate, in two parallel cohorts, the JAK1/2 inhibitor Ruxolitinib in combination with either Brentuximab or Pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who are eligible for treatment with Brentuximab or Pembrolizumab, respectively. 
The rationale for this study is based on the proven efficacy of Pembrolizumab and Nivolumab in relapsed or refractory cHL and the demonstrated clinical activity of Ruxolitinib in the same setting. Data obtained from patients previously treated with this combination suggest a potential improvement in therapeutic response.